Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-News: Abivax announces the release of its 2020 half-year financial report

eqs_en 
0 0 30.09.20
DGAP-News: Abivax announces the release of its 2020 half-year financial report
 

DGAP-News: ABIVAX / Key word(s): Half Year Results
Abivax announces the release of its 2020 half-year financial report

30.09.2020 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax announces the release of its 2020 half-year financial report


PARIS, France, September 30, 2020 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the publication of its 2020 half-year financial report. This document is available in electronic version on the website of the company (www.abivax.com) and on the website of the French financial markets authority, AMF (www.amf-france.org).


About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

******

Contacts

Abivax
Finance Department
Didier Blondel
[email protected]
+33 1 53 83 08 41		 Investors
LifeSci Advisors
Chris Maggos
[email protected]
+41 79 367 6254		 Press Relations & Investors Europe
MC Services AG
Anne Hennecke
[email protected]
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
[email protected]
+33 6 21 10 49 24
Public Relations France
DGM Conseil
Thomas Roborel de Climens
[email protected]
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
Marion Janic
[email protected]
+1 212 223 4017

30.09.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

1137910  30.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1137910&application_name=news&site_id=sharewise

Abivax S.A. Stock

€14.86
-2.240%
We can see a decrease in the price for Abivax S.A.. Compared to yesterday it has lost -€0.340 (-2.240%).

Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!